BiotechTubeBiotechTube
Home/Pipeline/SARS-CoV-2 Neutralizing Antibodies

SARS-CoV-2 Neutralizing Antibodies

COVID-19

DiscoveryCandidates identified

Key Facts

Indication
COVID-19
Phase
Discovery
Status
Candidates identified
Company
Adaptive Biotechnologies

About Adaptive Biotechnologies

Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.

View full company profile

Therapeutic Areas

OncologyAutoimmune DisordersInfectious DiseasesNeurodegenerative Disorders

Other COVID-19 Drugs

DrugCompanyPhase
COVID-19 Severity Prediction TestAge LabsDevelopment
Remdesivir (Veklury)Gilead SciencesApproved
mRNA-1273 (Spikevax)ModernaApproved
Investigational Oral COVID-19 AntiviralShionogiClinical
ZyCoV-DZydus LifesciencesApproved
BBIBP-CorVSinopharmApproved
Covovax™NovavaxApproved/Commercial
LY-CoV555 (Bamlanivimab)AbCelleraEmergency Use Authorization (Past)
ARCT-154 (Bivalent)Arcturus TherapeuticsPhase 1/2
LUNAR-COV19 (ARCT-021)Arcturus TherapeuticsPhase 1/2
Paxlovid (Nirmatrelvir) Manufacturing EnzymeCodexisCommercial